Drug Type Neural stem cell therapy |
Synonyms hCNSSC, HuCNSSC, HuCNSSC cells + [1] |
Target- |
Action stimulants |
Mechanism Cell replacements, Neurogenesis stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Age Related Macular Degeneration | Phase 2 | United States | 01 Jun 2015 | |
Geographic Atrophy | Phase 2 | United States | 01 Jun 2015 | |
Glycogen Storage Disease Type II | Phase 2 | United States | 01 Jun 2015 | |
Cervical spinal cord injury | Phase 2 | United States | 01 Oct 2014 | |
Cervical spinal cord injury | Phase 2 | Canada | 01 Oct 2014 | |
Spinal Injuries | Phase 2 | United States | 01 Oct 2014 | |
Spinal Injuries | Phase 2 | Canada | 01 Oct 2014 | |
Injury of thoracic spinal cord | Phase 2 | Canada | 01 Mar 2011 | |
Injury of thoracic spinal cord | Phase 2 | Switzerland | 01 Mar 2011 | |
Pelizaeus-Merzbacher Disease | Phase 1 | United States | 01 Nov 2009 |